{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041387","form_type":"8-K","ticker":"OCEA","cik":"0001869974","company_name":"Ocean Biomedical, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.214985+00:00","generated_at":"2026-06-08T02:45:54.548874+00:00","sec_items":["4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ocean Biomedical restates Q1/Q2 2023 financials over Backstop Agreement classification error","bullets":["Audit Committee on Nov 10 concluded prior Q1 and Q2 2023 financials should no longer be relied upon.","Issue follows SEC Staff interpretation on Forward Purchase Agreements; prepayment recorded as asset instead of equity.","Prepaid forward transaction and minimum maturity consideration should be classified as liabilities.","Prior earnings releases, guidance, and investor communications referencing those statements also unreliable."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041387","json":"https://secwatch.observer/filing/0001493152-23-041387.json","markdown":"https://secwatch.observer/filing/0001493152-23-041387.md","text":"https://secwatch.observer/filing/0001493152-23-041387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223041387/0001493152-23-041387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223041387/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:45:54.548874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"facd1b6792ca0fd36932b9bdae7bc0cb2a0e1846","claim":"Ocean Biomedical, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"On November 10, 2023, the Audit Committee of Ocean Biomedical, after considering the recommendations of management, concluded that Ocean Biomedical’s previously issued consolidated financial statements as of and for the quarters ended March 31, 2023 and June 30, 2023 (collectively, the “Previous Financial Statements”), included in Ocean Biomedical’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, its Registration Statement on Form S-1 (Registration No. 333-271392) effective June 22, 2023, and its Registration on Form S-1 (Registration No. 333-272859) effective July 7, 2023, should no longer be relied upon.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223041387/0001493152-23-041387-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}